Switch theme
Sign up to access all valuation multiples
bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.
2000
1
Last FY Revenue $20K
Last FY EBITDA -$0.9M
$0.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, bioXXmed achieved revenue of $20K and an EBITDA of -$0.9M.
bioXXmed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See bioXXmed valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $20K | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$0.9M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -4519% | XXX | XXX | XXX |
| EBIT | XXX | -$1.0M | XXX | XXX | XXX |
| EBIT Margin | XXX | -4862% | XXX | XXX | XXX |
| Net Profit | XXX | -$23.5M | XXX | XXX | XXX |
| Net Margin | XXX | -120369% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, bioXXmed's stock price is EUR 0 (or $0).
bioXXmed has current market cap of EUR 0.6M (or $0.6M), and EV of EUR 0.5M (or $0.5M).
See bioXXmed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $0.5M | $0.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, bioXXmed has market cap of $0.6M and EV of $0.5M.
bioXXmed's trades at 27.0x EV/Revenue multiple, and -0.6x EV/EBITDA.
Equity research analysts estimate bioXXmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
bioXXmed's P/E ratio is not available.
See valuation multiples for bioXXmed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $0.6M | XXX | $0.6M | XXX | XXX | XXX |
| EV (current) | $0.5M | XXX | $0.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 27.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -0.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialbioXXmed's revenue per employee in the last FY averaged $20K, while opex per employee averaged $1.0M for the same period.
bioXXmed's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
bioXXmed's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for bioXXmed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -4519% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $20K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 4962% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
bioXXmed acquired XXX companies to date.
Last acquisition by bioXXmed was XXXXXXXX, XXXXX XXXXX XXXXXX . bioXXmed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was bioXXmed founded? | bioXXmed was founded in 2000. |
| Where is bioXXmed headquartered? | bioXXmed is headquartered in Germany. |
| How many employees does bioXXmed have? | As of today, bioXXmed has 1 employees. |
| Is bioXXmed publicy listed? | Yes, bioXXmed is a public company listed on FRA. |
| What is the stock symbol of bioXXmed? | bioXXmed trades under T5O0 ticker. |
| When did bioXXmed go public? | bioXXmed went public in 2007. |
| Who are competitors of bioXXmed? | Similar companies to bioXXmed include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of bioXXmed? | bioXXmed's current market cap is $0.6M |
| Is bioXXmed profitable? | Yes, bioXXmed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
